Xingfu Li

Title: Innovations of Xingfu Li

Introduction

Xingfu Li is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating various diseases. With a total of 3 patents, his work has garnered attention in the scientific community.

Latest Patents

Xingfu Li's latest patents include an acylamino bridged heterocyclic compound, which is designed for the treatment or prevention of autoimmune diseases, tumors, and neurodegenerative diseases related to receptor-interacting protein kinase-1 (RIPK1). This compound can exist in various forms, including pharmaceutically acceptable salts and prodrugs. Another notable patent is for urea-substituted aromatic ring-linked dioxinoquinoline compounds, which serve as inhibitors for tyrosine kinases. These compounds are aimed at treating disorders related to tyrosine kinase, showcasing his innovative approach to drug development.

Career Highlights

Throughout his career, Xingfu Li has worked with Beijing Scitech-mq Pharmaceuticals Limited, where he has applied his expertise in pharmaceutical research and development. His contributions have been instrumental in advancing the company's goals in drug innovation.

Collaborations

Xingfu Li has collaborated with notable professionals in his field, including Qiang Zhang and Yansheng Liu. These partnerships have enhanced his research and development efforts, leading to impactful innovations.

Conclusion

Xingfu Li's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents reflect a commitment to addressing critical health challenges through scientific advancements.